Loading clinical trials...
Loading clinical trials...
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell popula...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of California, Davis
NCT05981807 · Human Papillomavirus Infection, Human Immunodeficiency Virus Infection, and more
NCT02214173 · Human Immunodeficiency Virus Infection
NCT02452242 · Human Immunodeficiency Virus Infections
NCT02561286 · Human Immunodeficiency Virus Infection (HIV), Sexually Transmitted Disease (STD)
NCT00711009 · Human Immunodeficiency Virus Infection
University of California Davis
Sacramento, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions